-
FDA approves expanded label for Teva's Azilect
JERUSALEM — Teva on Monday announced that the Food and Drug Administration approved an expanded label for Azilect (rasagiline tablets) from monotherapy and adjunct to levodopa to now include dopamine agonists. The approval reflects that Azilect can be used alone or with other Parkinson's disease medications.
-
Merck to acquire Idenix Pharmaceuticals for $3.9 billion
WHITEHOUSE STATION, N.J. — Merck and Idenix Pharmaceuticals on Monday announced that the companies have entered into a definitive agreement under which Merck will acquire Idenix for $24.50 per share in cash. The transaction, which values the purchase of Idenix at approximately $3.9 billion, has been approved by the boards of directors of both companies.